A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

TRC105 is a chimeric monoclonal antibody that targets CD105 (endoglin). Heavily pretreated patients with metastatic urothelial carcinoma received TRC105 at 15 mg/m(2) every 2 weeks on a 28-day cycle. Treatment was not associated with significant toxicities, but did not improve 6-month progression-fr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Genitourin Cancer
Main Authors: Apolo, Andrea B., Karzai, Fatima H., Trepel, Jane B., Alarcon, Sylvia, Lee, Sunmin, Lee, Min-Jung, Tomita, Yusuke, Cao, Liang, Yu, Yunkai, Merino, Maria J., Madan, Ravi A., Parnes, Howard L., Steinberg, Seth M., Rodriguez, Beatriz Walter, Seon, Ben K., Gulley, James L., Arlen, Philip M., Dawson, Nancy A., Figg, William D., Dahut, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583922/
https://ncbi.nlm.nih.gov/pubmed/27328856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.05.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados